A Study of Armed, Activated T-Cells in Patients With Advanced Pancreatic Cancer

Phase 1 Active not recruiting 7 enrolled Memorial Sloan Kettering Cancer Center University of Virginia · collab

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to find the safest dose and identify any bad side effects of EGFR-BATs (bispecific antibody-armed activated T cells) for people with advanced pancreatic cancer who have already received first-line standard chemotherapy.

Timeline

Start: 2019-10-17
Primary completion: 2027-04
Completion: 2027-04

Publications

Park JA, Santich BH, Xu H, Lum LG, Cheung NV. Potent ex vivo armed T cells using recombinant bispecific antibodies for adoptive immunotherapy with reduced cytokine release. J Immunother Cancer. 2021 May;9(5):e002222. doi: 10.1136/jitc-2020-002222.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	EGFR BATs	Cell therapy	7.5e+09 cells	—
Subject	EGFR BATs	Cell therapy	1e+10 cells	—

A Study of Armed, Activated T-Cells in Patients With Advanced Pancreatic Cancer

Summary

Timeline

Publications

Drugs

Indications